Introduction
Several US states have enacted laws to limit either opioid prescription days' supply or morphine milligram equivalents for the treatment of acute pain. 1 On July 1, 2018, Florida implemented House Bill 21 (HB21), which limits the days' supply of Schedule II opioids to 3 days for acute pain prescriptions. 2 Prescribers can extend to a 7-day supply if they document an exception. This quality improvement study aims to assess the outcomes associated with Florida's restriction law on opioid prescribing by evaluating the number of new opioid users and the number of units dispensed per prescription before and after the policy change.
Methods
This study was approved by the institutional review board at the University of Florida and was exempted from informed consent requirements because data were deidentified. This study follows the Standards for Quality Improvement Reporting Excellence (SQUIRE) reporting guideline.
We analyzed pharmacy prescription claims for opioids dispensed from January 2015 through 
Results
There were 54 409 individual opioid prescriptions dispensed to plan enrollees during the study period. After applying the inclusion criteria, there were a total of 8375 patients with 10 583 unique opioid starts.
Before HB21, 5.5 patients per 1000 enrollees per month began opioid use; there was a significant decrease in incidence immediately after the law was implemented to 4. The mean (SD) days' supply of opioids was 5.4 (6.5) days per prescription before the implementation of HB21 (Figure 2) . Implementation of the law was associated with a significant days' supply of opioids was 3 (1.5) days by the end of the study period.
Discussion
These findings suggest that implementation of HB 21 in Florida was associated with decreased opioid use and with changes in initial prescribing decisions. Our findings are more pronounced than those reported in analyses of laws in other states, [3] [4] [5] but it should be noted that Florida's 3-day restriction law is more stringent than other evaluated restriction laws. Generalizability of these findings is limited because the privately insured population was composed of patients who were younger and healthier than the typical opioid initiator. Future studies are needed to evaluate the downstream outcomes of these laws on use for appropriate and inappropriate treatment alternatives, as well as changes in nonmedical opioid use. Because there is a federal initiative to implement prescription 
